The collaboration supports NCI/CTEP efforts to implement novel strategies to correlate therapeutic treatment with patient response across a range of tumor types by incorporating the PanCancer IO 360TM
The PanCancer IO360 panel consists of 770 genes and is designed to characterize mechanisms of tumor immune evasion and identify targetable therapeutic pathways by leveraging several gene signatures to describe key biological processes. The panel is designed around the Tumor Inflammation Signature (TIS), an 18 gene signature which measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor that enriches for patient response to a variety of different cancer immunotherapies (Cesano & Warren https://www.ncbi.nlm.nih.gov/pubmed/29393888). The panel contains additional gene expression signatures to characterize the presence of immune cells within the tumor microenvironment and key biological activities such as IFN signaling, expression of key immune checkpoint molecules, antigenic burden (DNA mismatch repair status and MAGE expression), antigen processing and presentation, oxygenation/hypoxia, and vascularization.
“We believe that this collaboration presents a unique opportunity to apply in the translational research setting the latest generation of transcriptional profiling tools to NCI-sponsored clinical trials and to accelerate the development and implementation of novel immunotherapies and related diagnostics,” said
One of the first NCI-sponsored clinical trials to be included in the collaboration is led by Dr.
About the PanCancer IO360
NanoString’s PanCancer IO 360
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.